Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

September 27, 2005 16:15 ET

Sutura Expands Patent Protection for Vessel Closure Technology: Company Granted Allowance of Additional United States Patent for Superstitch Medical Device

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Sept. 27, 2005) - Sutura®, Inc. ("Sutura")(OTCBB:SUTU), a California-based medical device company, announced today that the United States Patent and Trademark Office has granted allowance of yet another patent for its vessel closure technology. This patent will further strengthen Sutura's intellectual property with respect to the Company's core SuperStitch vessel closure technology. The patent was allowed following the recent expansion of Sutura's sales force to market the patented SuperStitch technology.

The newly allowed patent builds on the base Sutura has already established for the development of its line of proprietary SuperStitch medical devices. Currently, the Company has been granted 13 patents for the SuperStitch technology including patents in China, Europe and the United States. The SuperStitch line of products is used in connection with cardiovascular and vascular procedures that require a puncture or incision to an artery. It is designed for use with or without an access device (e.g., trocar, sheath, or cannula) depending on the technique, for use during minimally invasive surgical procedures, fluoroscopically guided procedures, or in an open setting.

"This new patent will help ensure Sutura continues to build a leadership position and increase its competitive advantages in the $500 million U.S. closure device industry," said Anthony Nobles, CEO/President of Sutura. "We believe that Sutura has already gained important patent and technological advantage in the vessel closure device market: this patent adds to the already broad coverage of our IP Portfolio as we increase our strategic market position. Patents are the backbone of our technology and we intend to affirm our commitment to increasing our IP with each new advance."

About Sutura, Inc.

Sutura®, Inc. ( is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures. Within the United States the F8 & F6 SuperStitch device has been cleared by the FDA under section 510(k) of the Federal Food, Drug, and Cosmetic Act ("FDC Act") for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch F8 & F6 is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may","appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications